NAD/NADH Ratio

Your cells run on a constant electron shuffle between two forms of the same molecule. When that shuffle falters, energy production drops, damage accumulates, and the earliest signs show up long before you feel sick. The NAD/NADH ratio (nicotinamide adenine dinucleotide, oxidized to reduced form) is one of the few readouts that captures how balanced this shuffle is.

This is a research-grade marker, not a standard clinical test. Reference ranges are still being defined, and interpretation depends heavily on what fluid or tissue was measured. But for anyone tracking energy metabolism, mitochondrial health, or the effect of an NAD-boosting supplement, it offers a window that routine labs do not.

What This Ratio Actually Reflects

NAD+ is the oxidized form of the molecule. NADH is the reduced form, meaning it is carrying a hydride (two electrons and a proton). Your cells convert NAD+ to NADH during the breakdown of food and back again when NADH donates its electrons to the mitochondria, the tiny compartments inside cells that generate energy. The balance between these two forms tells you how efficiently your cells are running that cycle.

A higher ratio usually means your cells are in a more oxidized state, which supports efficient energy production. A lower ratio means the balance has shifted toward the reduced form, a state called reductive stress. This state directly impairs the anaerobic route (glycolysis) at a step called GAPDH, which needs NAD+ to work. It also disrupts the aerobic route (oxidative phosphorylation) in a different way, causing an electron traffic jam in the mitochondria that produces reactive oxygen species and reduces ATP output, the molecule that powers everything from muscle contraction to thinking.

The ratio also connects to hundreds of downstream reactions. It regulates enzymes across glycolysis, the citric acid cycle (your cells' main energy-generating loop), and fatty acid oxidation. It shapes the activity of sirtuins, PARPs, and CD38, three enzyme families involved in DNA repair, inflammation, and aging biology.

Why a Single Number Only Tells Part of the Story

The ratio is not uniform across your body. Inside a single cell, the ratio in the nucleus and cytoplasm sits strongly favoring the oxidized form. Inside mitochondria, the balance is much closer between the two forms. Different tissues carry different balances. Plasma values are much lower and often nearly balanced, depending on the study.

This is why a blood-based ratio is a useful signal but not a complete picture. It reflects the extracellular pool your circulation carries, which tracks broad patterns of disease and metabolic health without perfectly mirroring what is happening inside your muscles, brain, or heart.

Aging and Sex Differences

Plasma NAD+ levels have been reported to decline with age in cross-sectional studies, driving the ratio down over time. NADH tends to stay stable, so it is mostly the loss of NAD+ that shifts the balance. Not every study agrees. One profiling study in 299 healthy adults aged 18 to 70 found redox metabolites remained broadly stable across ages.

In a study of 205 adults, women had higher plasma NAD+/NADH ratios than men. That sex difference narrowed with age and tracked more closely with biological aging markers like skin autofluorescence and pulse wave velocity than with chronological age.

Mitochondrial and Metabolic Disease

The strongest human evidence links a lower ratio to mitochondrial dysfunction. In patients with MELAS (a mitochondrial disorder caused by the m.3243A>G mutation), a plasma panel of analytes mechanistically tied to elevated NADH/NAD+ distinguished patients from controls and correlated with severity measures including Karnofsky status, a functional scoring system doctors use to gauge how limited someone is by illness.

In patients with Leigh syndrome, another mitochondrial disorder, NADH was elevated in patient-derived cell samples while NAD+ was unchanged. The authors argued that NADH accumulation itself may track disease severity more closely than the ratio, and that measuring it directly may outperform lactate, the standard indirect marker doctors use.

In one clinical example, patients with mitochondrial myopathy who had lower muscle and whole-blood NAD+ at baseline showed the greatest benefit from niacin (nicotinic acid) treatment. Niacin restored blood NAD+ up to 8-fold and returned muscle NAD+ to control levels. This is the closest current example of NAD measurements guiding a treatment decision.

Heart and Cardiovascular Disease

Human failing hearts from patients with dilated cardiomyopathy show reductions in both NAD+ and the NAD+/NADH ratio compared to healthy hearts. This condition carries high risk of heart failure and sudden cardiac death, so redox imbalance in the heart is not a benign finding when it appears.

In diabetic cardiomyopathy, a lower ratio and higher acetyl-CoA/CoA ratio (another energy-balance readout) are linked to progressive cardiac dysfunction. Direct human cardiac measurements remain limited, in part because NADH and NADPH give off nearly identical signals during measurement, making them hard to separate cleanly.

Diabetes and Metabolic Stress

In diabetes, the ratio drops in what researchers call pseudohypoxia, a state where cells behave as if they are oxygen-starved even when oxygen is available. Short-term exposure of human red blood cells to high glucose lowered their NAD+/NADH ratio, and this drop was prevented in cellular models by an aldose reductase inhibitor, a drug class that blocks a pathway involved in diabetic complications. Aldose reductase inhibitors have not, however, demonstrated clinical efficacy in human trials for diabetic complications, so this remains a mechanistic finding rather than a therapeutic strategy.

Oxidative stress in diabetic tissues activates PARP, an enzyme family that consumes NAD+ rapidly, further raising the NADH/NAD+ ratio and worsening the imbalance.

Brain, Mood, and Neurodegeneration

Using a specialized brain scan called 31P-MRS, researchers found a reduced brain NAD+/NADH ratio in patients with chronic schizophrenia and first-episode schizophrenia compared to matched healthy controls. Unaffected siblings of psychosis patients showed lower NAD+ than controls, but their ratio reduction was not statistically significant, suggesting the ratio tracks with disease expression more than genetic risk alone.

In a small phase 2 trial in patients with Parkinson's disease or multiple sclerosis, brain NAD+/NADH rose after 12 or more weeks of treatment with CNM-Au8, a nanomedicine designed to support cellular energetics. This shows the ratio can respond to targeted interventions and be used to confirm a drug is reaching its intended target.

Pregnancy and Growth

In a study of 50 women, patients with intrauterine growth restriction (IUGR), where a fetus grows more slowly than expected, had lower plasma and placental NAD+ levels and higher NADH, producing a lower ratio. This shift accompanied increased lipid peroxidation and other oxidative injury markers, tying the redox change to a clinically adverse pregnancy phenotype.

Why One Reading Is Not Enough

NAD metabolism is dynamic. NAD has a short half-life, roughly 1 to 2 hours in the cytoplasm and nucleus and about 8 hours in mitochondria, so any single blood draw captures a snapshot of a fast-moving system. Steady-state values also miss turnover: if consumption and synthesis are both elevated, the concentration may look normal while the underlying biology is stressed.

For meaningful use, get a baseline. If you start an NAD-boosting supplement or make significant lifestyle changes, retest in 3 to 6 months. Then retest at least annually to build a trajectory you can act on. A supplement study in adults aged 40 to 65 showed serum NAD+/NADH rising at 30 days and again at 60 days on 300 mg of nicotinamide mononucleotide daily. Retesting is how you know whether an intervention is actually shifting your own biology, not just someone else's average.

When Results Can Be Misleading

The ratio is compartmentalized. A plasma or blood measurement reflects your extracellular pool. It does not directly tell you what is happening inside your mitochondria or brain. This is the single most important caveat for interpretation. If your plasma ratio looks normal but you have symptoms of mitochondrial or metabolic stress, that discrepancy is expected, not a sign the test failed.

Measurement method matters. NADH and NADPH give off nearly identical signals in many assays, and older kit-based methods estimate NAD+ indirectly under acidic conditions that can degrade NADH during processing. Direct LC-MS/MS (a lab technique that separates and identifies molecules by mass) is more precise, but not every lab uses it. If you retest, use the same lab and method.

Fasting versus fed states and the timing of your last meal can shift the reading. Fasting has been associated with higher NAD+ levels in some model systems, though classic rat data actually showed the cytoplasmic ratio dropped during starvation, so the human plasma effect is not settled. Acute high-glucose exposure can rapidly lower the ratio in red blood cells. For consistency, standardize the timing and fasting state of each draw.

What to Do With an Unexpected Result

If your ratio is lower than expected, the first step is to repeat the test with the same method and timing to rule out measurement variability. If the result holds, the pattern to look for is a combination: low ratio plus elevated lactate, plus fatigue-dominant symptoms, plus a family or personal history of mitochondrial or metabolic disease points toward a workup for mitochondrial dysfunction.

Companion tests that add context include a full NAD profile (NAD+, NADH, NADP+, NADPH separately), fasting insulin, HbA1c, and inflammatory markers like hs-CRP. If cardiac symptoms are involved, a lipid panel with ApoB and cardiac imaging may be relevant. If cognitive or neurological symptoms are prominent, a specialist who works on mitochondrial or neurodegenerative disease is the right conversation to have. For most people, the value comes not from a single number but from a trajectory tracked alongside broader metabolic labs.